Galmed Pharmaceuticals
GLMD
22 hedge funds and large institutions have $1.7M invested in Galmed Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 5 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
0.01% less ownership
Funds ownership: 0.06% → 0.06% (-0.01%)
4% less funds holding
Funds holding: 23 → 22 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
62% less capital invested
Capital invested by funds: $4.47M → $1.7M (-$2.77M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WWM
Western Wealth Management
Golden,
Colorado
|
+$54.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$43.3K |
| 3 |
Millennium Management
New York
|
+$36.8K |
| 4 |
Renaissance Technologies
New York
|
+$29.2K |
| 5 |
Morgan Stanley
New York
|
+$28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$412K |
| 2 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$318K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$41.8K |
| 4 |
BlackRock
New York
|
-$14K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$4.97K |
GLMD Hedge Fund Activity: Q2 2022 in Review
22 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2022, worth a combined $1.7M — down 62% from $4.47M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of GLMD and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 7 added.
The largest buyer was Western Wealth Management, opening a new position worth an estimated $54.4K. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $412K sold.
- 22 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2022, down from 23 in Q1 2022.
- Funds reported $1.7M of Galmed Pharmaceuticals stock for Q2 2022, down 62% quarter-over-quarter.
- 4 funds opened new Galmed Pharmaceuticals positions in Q2 2022 and 5 closed out, a net change of -1 holder.
- The largest Galmed Pharmaceuticals buyer in Q2 2022 was Western Wealth Management, an estimated $54.4K added.
- The largest Galmed Pharmaceuticals seller in Q2 2022 was Nantahala Capital Management, an estimated $412K sold.
Based on aggregated 13F filings for Q2 2022.